Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gerhard Sperl is active.

Publication


Featured researches published by Gerhard Sperl.


Biochemical Pharmacology | 2002

Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve β-catenin and cyclin D1 down-regulation

Han Li; Li Liu; Mary David; Clark M. Whitehead; Ming Chen; John Fetter; Gerhard Sperl; Rifat Pamukcu; W. Joseph Thompson

Exisulind and its analogues are inhibitors of cyclic GMP phosphodiesterases (PDEs) that have been shown to activate and induce protein kinase G, resulting in the induction of apoptosis in colon cancer cells. These drugs also reduce beta-catenin protein levels and decrease cyclin D1 mRNA levels in SW480 cells. Herein we report on studies pertaining to exisulind regulation of beta-catenin levels and activity in colon tumor cells. Exisulind and its higher-affinity PDE analogues, (Z)-5-fluoro-2-methyl-(4-pyridylidene)-3-(N-benzyl)-indenylacetamide hydrochloride (CP461) and (Z)-1H-indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methylene] (CP248), reduced beta-catenin, including the nuclear beta-catenin in SW480 cells (EC(50) approximately 200 microM, 1 microM, and <1 microM, respectively). The 50% reduction of beta-catenin was seen in 8-14 hr. There was no change in beta-catenin mRNA. Exisulind-induced beta-catenin reduction was blocked by the proteasomal inhibitor MG132 (Z-leu-Leu-Leu-CHO), indicating that the effect of exisulind involved ubiquitin-proteasomal degradation. A consequence of reduced beta-catenin in SW480 cells was that exisulind, CP461, and CP248 caused a concentration- and time-dependent decrease in cyclin D1 levels (EC(50) approximately 300 microM, 1 microM, and <1 microM, respectively) in 4 hr. The effect was via decreased cyclin D1 mRNA levels. Exisulind-induced degradation of beta-catenin was not blocked by the inhibition of caspase-3 activity and/or apoptosis, and some SW480 cells showed a reduction in beta-catenin levels before the appearance of early apoptosis indicators. Expression of the N-terminal 170 amino acid fragment of beta-catenin reduced the effects of beta-catenin degradation, cyclin D1 reduction, and the apoptosis response to exisulind. These results indicate that exisulind-induced beta-catenin degradation precedes the induction of apoptosis and that the down-regulation of inappropriate beta-catenin-activated genes accounts in part for the pro-apoptotic effects of exisulind and CP461 in colon tumor cells.


Journal of Labelled Compounds and Radiopharmaceuticals | 1999

Synthesis of radioactive sulindac‐sulfone‐lactone via sulfonium salt and 14C alkylhalide

Gerhard Sperl; Rifat Pamukcu; Klaus Brendel; Paul H. Gross

A new method of radioactive labeling via sulfonium salts and 14C alkylhalides is reported, along with a novel synthesis of (E)-rac-(2′-buten-1′,4′-olido)-[3′,4′:1,2]-6-fluoro-2-methyl-3-(4-[14C-methyl]-sulfonylbenzylidene)-indan (scheme 1, compound 14CH3-SO2-L]), a drug that showed very high activity, when tested in various tumor cell lines (1). Copyright


Cancer Research | 1995

Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis

Gary A. Piazza; Alanna L. Kulchak Rahm; Mary Krutzsch; Gerhard Sperl; Nancy Shipp Paranka; Paul H. Gross; Klaus Brendel; Randall W. Burt; David S. Alberts; Rifat Pamukcu; Dennis J. Ahnen


Cancer Research | 1997

Sulindac Sulfone Inhibits Azoxymethane-induced Colon Carcinogenesis in Rats without Reducing Prostaglandin Levels

Gary A. Piazza; David S. Alberts; Lee J. Hixson; Nancy Shipp Paranka; Han Li; Tyler S. Finn; Cheryl L. Bogert; Jose Guillen; Klaus Brendel; Paul H. Gross; Gerhard Sperl; Justine M. Ritchie; Randall W. Burt; Lansing G. Ellsworth; Dennis J. Ahnen; Rifat Pamukcu


Cancer Research | 2000

Exisulind Induction of Apoptosis Involves Guanosine 3′,5′-Cyclic Monophosphate Phosphodiesterase Inhibition, Protein Kinase G Activation, and Attenuated β-Catenin

W. Thompson; Gary A. Piazza; Han Li; Li Liu; John Fetter; Bing Zhu; Gerhard Sperl; Dennis J. Ahnen; Rifat Pamukcu


Biochemical Pharmacology | 1999

Sulindac Derivatives Inhibit Growth and Induce Apoptosis in Human Prostate Cancer Cell Lines

Jin T. E. Lim; Gary A. Piazza; Edward K. Han; Thomas M. Delohery; Han Li; Tyler S. Finn; Ralph Buttyan; Hirofumi Yamamoto; Gerhard Sperl; Klaus Brendel; Paul H. Gross; Rifat Pamukcu; I. Bernard Weinstein


Journal of Pharmacology and Experimental Therapeutics | 2001

Cyclic GMP-Dependent Protein Kinase Activation and Induction by Exisulind and CP461 in Colon Tumor Cells

Li Liu; Han Li; Tashandra Underwood; Marti Lloyd; Mary David; Gerhard Sperl; Rifat Pamukcu; W. Joseph Thompson


Archive | 1998

Method of inhibiting neoplastic cells with benzimidazole derivatives

Gerhard Sperl; Rifat Pamukcu; Ulrich Ixkes; Gary A. Piazza


Archive | 1997

Substituted benzylidene indenyl formamides, acetamides and propionamides

Gerhard Sperl; Paul H. Gross; Klaus Brendel; Rifat Pamukcu; Gary A. Piazza


Archive | 1998

[4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia

Xiaojing Wang; Gerhard Sperl; Paul H. Gross; Rifat Pamukcu; Gary A. Piazza

Collaboration


Dive into the Gerhard Sperl's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gary A. Piazza

University of South Alabama

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Han Li

OSI Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Dennis J. Ahnen

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar

Li Liu

Columbia University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

W. Joseph Thompson

University of Texas at Austin

View shared research outputs
Researchain Logo
Decentralizing Knowledge